Compounds for the treatment of Alzheimer's disease

Details Compounds for the treatment of Alzheimer's disease Compounds for the treatment of Alzheimer's disease

1993-10-19

2000-11-21

Berch, Mark L

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

540557, 540581, C07D49106, C07D48706, A61K 31553, A61K 3155

Patent

active

061503541

ABSTRACT:
A method of treating Alzheimer's disease and related dementias by treatment with analogs of galanthamine, particularly those wherein the methoxy and hydroxy substituents are replaced by, for example carbamate groups, the methoxy is replaced by hydroxy and esters of galanthamine and O-desmethyl galanthamine. Many of the useful compounds are novel.

REFERENCES:
patent: 3673177 (1972-06-01), Morleck et al.
Rogers, Neurology 50, 136, 1988.
Document History for NDA 20-690 Aricept, pp. 34, 35, 61-64, Aug. 29, 1996.
Summar Basis for Approval of NDA 17-993, Apr. 1977.
Fitten, Am. J. Psychiatry 147, 239, Feb. 1990.
Molloy, Can Med. Assoc. J. 144(1), 29, Jan. 1991.
Wilcock, Age and Ageing 22, 316, 1993.
Weinstein, J. Neurology 238, 34, 1991.
Letters from Pirozzolo and Others, New England Journal of Medicine 346(25), 1603, Jun. 18, 1987.
Gauthier, New England Journal of Medicine, 322(18) 1272, May 3, 1990.
Davis, New England Journal of Medicine, 327(18) 1253, Oct. 1992.
Davies, The Lancet Jul. 15, 1989, p. 163, Jul. 15, 1989.
Claman, Alz. Dis. and Associated Disorders 5, Suppl 1, S49, 1991.
F-D-C Reports ("The Pink Sheets") 53(12) 1, 4-9, Mar. 25, 1991.
Thal, "Alzheimer Disease" (Terry, Ed, RAven Press, NY) p 431-444, 1994.
"FDA" New England Journal of Medicine 324(5), 349, Jan. 31, 1991.
Chatellier, BMJ 300, 495, Feb. 24, 1990.
Levy, The Lancet Feb. 7, 1987, p. 322.
Letters by Wilcock and others, BMJ 300, 939, Apr. 7, 1990.
Goodman and Gilman's Pharmaceutical Basis of Therapeutics, 6th Ed, pp. 100-119, 1980.
Irwin, J. Phar Exp Ther. 136, 20-25, 1962.
Harbsugh, Ann NY Acad Sci 531, 174-179, 1988.
Penn, Neurology 38, 219, 1988.
Kuzuya, Text vesion of USP 4713376, Dec. 1987.
Leber, "Alzheimer's Disease: From Molecular Biology to Therapy", pp. 579-584, 1996.
Eagger, Dementia 2, 207, 1991.
Giacobini, Ed, "Current res. in Alz. Therapy: Cholinesterase Inhibitors" pp. 237-245, 1988.
PDR, 52nd Edition, p. 14, 1998.
http://www.planetrx.com/product/rx/shelf/info/1088.sub.-- introduction.asp, 1999.
PDR, 49th Edition, p. 1826-1830, 2162-3, 1995.
Knapp, JAMA 271, 985, 1994.
Kluger, Psychiatric Clinics of North America 14(2), 309, 1980.
Welsh, Abstract of Arch Neurol. 49(5), 448, 1992.
http://www.phrma.org/issues/lead.html, 1998.
Kewist, ed, Pharm. Interventions on Central Cholinergic Mechanisms in Senile Dementia, p 233, 1989.
DSM-III-R, p. 119-121, 1987.
Joachim, Ann. Neurol 24, 50-56, 1988.
Jellinger, Abstract for J. Neurol Sci 95(3) 239, Mar. 1995.
Bergener, Ed, Diagnosis and Treatment of Senile Dementia, pp. 164-173, 1989.
Giacobini, Alzheimer's Disease: Threapeutic Strategies, pp. 140-144, 1994.
Pontecorvo, 6th Int. Conf. on Alz. Dis. Related Dis., p. S7, Abstract 26 & unnumbered slide, Jul. 1998.
Kewitz, Davis, KatzFirst Eur. Cong. Pharmacology, unnumbered abstract, Jun. 1995.
Script #1948, p 21, Aug. 1994.
Massoulie, Ann. Rev. Neurosci. 5, 57-106, 1982.
Jenden, Ed, Cholinergic Mechanisms and Psychopharmacology, pp. 125-137, 1977.
Goodman and Gilman's Pharmaceutical Basis of Therapeutics, 6th Ed, pp. 56-90, 1980.
Sherman, Alz. Disease And Associated Disorders 2, 216, 1988.
Liston, Alz. Disease And Associated Disorders 2, 219, 1988.
Thal, J Am Geriatric Soc 37, 42, 1989.
Stern, Ann Neurol 22, 306, 1987.
Jenike, J. Clin Psychiatry 51, 3-7, 1990.
Harrell, J Am Geriatric Soc 38, 113, 1990.
Iqbal, Ed, "Alzheimer's Disease and Related Disorders" (Alan Liss, Inc, New York) p1291-1299, 1989.
Abdallah, Phytochemistry vol. 39, 477, 1995.
Sarter, Psychopharmacology 107, 144-159, 1992.
Han, Eur. J. Med. Chem 27, 673-687, 1992.
Chemical Abstracts, vol. 61, No. 12, Dec. 7, 1994, Abstract No. 14727g.
Chemical Abstracts, vol. 61, No. 11, Nov. 23, 1964, Abstract Nos. 13357 and 13358.
Chemical Abstracts, vol. 74, No. 21, May 24, 1971, p. 423-424, Abstract No. 112265.
Daleva, Eksp Med. Morf. 1963 1:38-46 from Abstract Bulg. Sci. Lit. Med. Phys. Cultur. 6(3) Abstract 359 (1963) Translation submitted.
J.R. Boissier, et al. CA56, 2515a.
R.D. Penn, et al. Neurology (1988), 38:219-222.
Friedman, et al. Nature Medicine (1996), Dec. 2 (12): 1382-5 (Abstract).
Benjamin Calesnick, Chapter 6 of Drill's Pharmacology in Medicine (1971), p:99-124.
Sweeney, Bachman and Coyle's, Psychopharmacology (1990), 102:191-200.
Doctor's Guide Website--Galantamine Improves Memory and Learning Ability in Alzheimer's Patients, 1998--Janssen Press Release, (Jul. 20, 1998.
P. Dal-Bianco, et al. Galanthimine Treatment in Alzheimer's Disease, Presented at the 19th Central European Neurobiological Sypmposium-CNS-19, Vienna, Jun. 29-Jul. 1, 1989.
Pontecorvo, et al. Slide presented at the 6th International Conference on Alzheimer's Disease and Related Disorders, Amsterdam, 18-23, Jul. 1998.
Summers, et al. The New England Journal of Medicine (1986), vol. 315 (20): 1241-5.
Knapp, et al. JAMA, Apr. 6, 1994, vol. 271, No. 13, pp. 985-991.
Vincent, et al., Abstract. 237.4. Society for Neuroscience 1987.
Zhang, et al., Chung Kuo Yao Ki Hsueh Pao (1991) 12 (3):250-2 (Abstract).
Xu, et al., Chung Ko Yao Li Hsueh Pao (1995), 15 (5), 391-5 (Abstract).
Nelson, P., Table of Contents for AD Diagnosis and Treatment Guide, last updated Sep. 8, 1998.
W.N. Aldridge, et al., Acta. Pharmacol. et. Toxicol., 1981, 49, Suppln. V. 3-6.
Anon New Chemicals Markedly Inhibit Cholinesterase, Government Reports, Announcements and Index, Issue 23, 1986.
I. Kimura, et al., Japanese J. Pharmacology, May 1993, 62 (1):35-41 (Abstract Only).
Davis, et al., Am. J. Psychiatry, 144:4, Apr. 1987, pp. 468-471.
Gibson, et al., Lancet, Mar. 23, 1985, pp. 695-696.
Sharpless and Thal. Lancet, Jun. 15, 1985, pp. 1397-1398.
Somani and Khalique, J. Anal. Toxicol. (1985), 9:71-75.
Thal. et al. Ann. Neurol. (1983) 13:491-496.
Lamb, et al. , Drugs and Aging, Dec. 11, 1997 (6), pp. 490-496.
Scrip 1875, p. 12, (Nov. 23, 1998.
Vincent, Abstract No. 27.12, Society for Neuroscience, 1988.
Sweeney, et al., Psychopharmacology (1990) 102:191-200.
Bores, et al., Drugs of the Future, 1996, 21 (6):627-636.
Abstract of Cummings, Neurology 50, p1214 (1998).
Abstract of S.L. Rogers, et al., Neurology, vol. 50, Jan. 1998, pp 136.
Abstract of J. Corey-Bloom, International Journal of Geriatric Psychopharmacology (1988) 1.
M. Farlow, JAMA, Nov. 11, 1992, vol. 268, No. 18, pp. 2523-2529.
Recent News, Novartis Website, May 13, 1998.
Rogers, S.L. et al. "A 24-week, double-blind . . . " Neurology, vol. 50, Jan. 1998, pp. 136-145.
Reisberg, B. "The Global Determination . . . " Am. J. Psychiatry, Sep. 1982, 139 (9), pp. 1136-1139.
PR Newswire--Forest Laboratories Receives a Non-Approvable, Letter from FDA on Synapton, Nov. 18, 1998.
Bhasker, P.A. "Medical Management . . . " Antiseptic, vol. 71, No. 1 pp. 45-47. (1974.
Bubeva-Ivanova, L. "Amaryllidaceae alkaloids . . . " Chemical Abstracts, vol. 57, (1962) Abstract No. 12560 e, Columbus, Ohio.
Combes, G. et al. "Galanthaminone" Chemical Abstracts, vol. 58, (1963), Abstract No. 11411b, Columbus, Ohio, pp. 1805-1809.
Laiho, S.M. et al. "Narcissamine . . . " Chemical Abstracts, vol. 61, (1964), Abstract No. 14732f.
Koizumi, J. et al. "Galanthamine . . . " Chemical Abstracts, vol. 61, (1964) & Chem. Pharm. Bull. (Tokyo) 12(6), 696-705(1964).
Abdusamatou, A. et. al. "Alkaloids from Ungernia . . . " Chemical Abstracts, vol. 59, (1963) Abstract No. 3716f, Columbus, Ohio; & Dokl. Akad. Nauk. UZ. SSR 20(1), 18-21 (1963).
Minami, S. et al. "Galanthamine . . . " Chemical Abstracts, vol. 61, (1964), Abstract No. 14727 g, (& Chem. Pharm. Bull. (Tokyo) 12(9) 1012-20 (1964.
Kametani, T. et al "Synthesis of Heterocyclic . . . " Chemical Abstracts, vol. 74, (1971) Abstract 1122652, Columbus, Ohio. & J. Chem. Soc. C. (1971), (3) 590-2.
Kametani, T. et al. "Synthesis of Analgesics . . . " Chemical Abstracts, vol. 78, (1973) p. 507, Abstract No. 11158 T, Columbus, Ohio, US & J. Heterocycl. Chem. (1973), 10(1), 35-7.
Chemical Abstracts, vol. 77, 1972, p. 515, Abstract No. 48690S, Columbus, Ohio, & JP-A-72 13 919 (Grelan Pharmaceutical Co. LTD) (Apr. 26, 1972).
Kametani, T. et al. "Syntheses of Narwedine-Type Enones . . . " Chemical Abstracts, vol. 77, (1972) p. 526, Abstract No. 62186 p. Co

Affiliated with

Also associated with

Rating

Compounds for the treatment of Alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds for the treatment of Alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of Alzheimer's disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1257353